Literature DB >> 17285022

Minimizing and managing bleeding after percutaneous nephrolithotomy.

Keith L Lee1, Marshall L Stoller.   

Abstract

PURPOSE OF REVIEW: As urologists will continue to rely on percutaneous nephrolithotomy, a clear understanding of its associated bleeding risks and management is mandatory. RECENT
FINDINGS: Despite advances in lithotripsy technology, bleeding continues to be a cause of patient morbidity in percutaneous nephrolithotomy. Although most patients can be managed conservatively, a subset of patients will require endovascular embolization for vascular control. Investigators have identified risk factors and described management options. The use of different dilators and tract size continues to be examined. Additionally, novel applications of proclotting agents as well as direct renal and tract electrocauterization immediately postpercutaneous nephrolithotomy have been reported to decrease transfusions. Finally, initial access obtained by the urologist is associated with less bleeding and higher stone-free rates.
SUMMARY: Optimal renal access is the most critical factor influencing surgical success and minimizing overall blood loss. Although real-time ultrasonography may add to the safety of the initial access, surgeon experience is the key factor. As such, the urologist must be actively involved in tract placement. Clinically significant bleeding can be treated conservatively in a majority of cases with tamponade nephrostomy tubes with or without transfusions. Arterial hemorrhage, pseudoaneurysms, and arterial-venous fistulas, however, require prompt intervention with angiographic embolization.

Entities:  

Mesh:

Year:  2007        PMID: 17285022     DOI: 10.1097/MOU.0b013e328010ca76

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  12 in total

1.  Nephrostolithotomy.

Authors:  Darryl A Zuckerman; Alena Desai
Journal:  Semin Intervent Radiol       Date:  2011-12       Impact factor: 1.513

Review 2.  [Biopsies of the kidney, prostate and urinary bladder].

Authors:  F M E Wagenlehner; W Weidner; T Diemer; B Altinkilic
Journal:  Urologe A       Date:  2014-05       Impact factor: 0.639

Review 3.  Percutaneous nephrolithotomy: complications and how to deal with them.

Authors:  Daniel A Wollin; Glenn M Preminger
Journal:  Urolithiasis       Date:  2017-11-17       Impact factor: 3.436

4.  Peri-Operative Factors Affecting Blood Transfusion Requirements During PCNL: A Retrospective Non-Randomized Study.

Authors:  Chinnakhet Ketsuwan; Narutsama Pimpanit; Yada Phengsalae; Charoen Leenanupunth; Wisoot Kongchareonsombat; Premsant Sangkum
Journal:  Res Rep Urol       Date:  2020-07-22

Review 5.  Status quo of percutaneous nephrolithotomy in children.

Authors:  Sotirios Bogris; Athanasios G Papatsoris
Journal:  Urol Res       Date:  2010-02

6.  Endovascular covered stenting for the management of post-percutaneous nephrolithotomy renal pseudoaneurysm: a case report.

Authors:  Prodromos Philippou; Konstantinos Moraitis; Tamer El-Husseiny; Hassan Wazait; Junaid Masood; Noor Buchholz
Journal:  J Med Case Rep       Date:  2010-09-23

7.  Complications of Percutaneous Nephrolithotomy Classified by the Modified Clavien Grading System: A Single Center's Experience over 16 Years.

Authors:  Tae Seung Shin; Hyuk Jin Cho; Sung-Hoo Hong; Ji Youl Lee; Sae Woong Kim; Tae-Kon Hwang
Journal:  Korean J Urol       Date:  2011-11-17

8.  Single-step renal dilatation in percutaneous nephrolithotomy: A prospective randomised study.

Authors:  Hani H Nour; Ahmad M Kamal; Ahmad S Zayed; Hisham Refaat; Mohamed H Badawy; Tarek R El-Leithy
Journal:  Arab J Urol       Date:  2014-07-02

9.  Percutaneous nephrolithotomy: Current concepts.

Authors:  Fabio C Vicentini; Cristiano Mendes Gomes; Alexandre Danilovic; Elias A Chedid Neto; Eduardo Mazzucchi; Miguel Srougi
Journal:  Indian J Urol       Date:  2009-01

10.  Metachronous renal vein and artery injure after percutaneous nephrostolithotomy.

Authors:  Chaojun Wang; Shanwen Chen; Fuqing Tang; Baihua Shen
Journal:  BMC Urol       Date:  2013-12-05       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.